{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:28:48Z","timestamp":1791340128211,"version":"4.3.1"},"reference-count":102,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues includes new criteria for the diagnosis of these disorders. Somatic mutations in the 3 driver genes, that is, JAK2, CALR, and MPL, represent major diagnostic criteria in combination with hematologic and morphological abnormalities. PV is characterized by erythrocytosis with suppressed endogenous erythropoietin production, bone marrow panmyelosis, and JAK2 mutation. Thrombocytosis, bone marrow megakaryocytic proliferation, and presence of JAK2, CALR, or MPL mutation are the main diagnostic criteria for ET. PMF is characterized by bone marrow megakaryocytic proliferation, reticulin and\/or collagen fibrosis, and presence of JAK2, CALR, or MPL mutation. Prefibrotic myelofibrosis represents an early phase of myelofibrosis, and is characterized by granulocytic\/megakaryocytic proliferation and lack of reticulin fibrosis in the bone marrow. The genomic landscape of MPNs is more complex than initially thought and involves several mutant genes beyond the 3 drivers. Comutated, myeloid tumor-suppressor genes contribute to phenotypic variability, phenotypic shifts, and progression to more aggressive disorders. Patients with myeloid neoplasms are at variable risk of vascular complications, including arterial or venous thrombosis and bleeding. Current prognostic models are mainly based on clinical and hematologic parameters, but innovative models that include genetic data are being developed for both clinical and trial settings. In perspective, molecular profiling of MPNs might also allow for accurate evaluation and monitoring of response to innovative drugs that target the mutant clone.<\/jats:p>","DOI":"10.1182\/blood-2016-10-695957","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T21:00:18Z","timestamp":1482872418000},"page":"680-692","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":228,"title":["Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9504","authenticated-orcid":false,"given":"Elisa","family":"Rumi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6984-8817","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111903081715000_B1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"2019111903081715000_B2","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"20","key":"2019111903081715000_B3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7037","key":"2019111903081715000_B4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2019111903081715000_B5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903081715000_B6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"2019111903081715000_B7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"2019111903081715000_B8","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"5","key":"2019111903081715000_B9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903081715000_B10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903081715000_B11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111903081715000_B12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019111903081715000_B13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111903081715000_B14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111903081715000_B15","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111903081715000_B16","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111903081715000_B17","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111903081715000_B18","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111903081715000_B19","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2019111903081715000_B20","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","article-title":"How I treat essential thrombocythemia","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2019111903081715000_B21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111903081715000_B22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111903081715000_B23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"20","key":"2019111903081715000_B24","article-title":"The 2016 WHO criteria for the diagnosis of polycythemia vera: benefits and potential risks [comment]","volume":"127","author":"Ethier","year":"2016","journal-title":"Blood"},{"key":"2019111903081715000_B25","first-page":"44","article-title":"Primary myelofibrosis","volume-title":"WHO Classification of Tumours of Haematolopoietic and Lymphoid Tissues","author":"Thiele","year":"2008"},{"issue":"4","key":"2019111903081715000_B26","doi-asserted-by":"crossref","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"2019111903081715000_B27","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B28","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2016-02-698951","article-title":"Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia","volume":"128","author":"Kapralova","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2019111903081715000_B29","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2016-04-711283","article-title":"Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera","volume":"128","author":"Lanikova","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903081715000_B30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903081715000_B31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111903081715000_B32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","article-title":"Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes","volume":"27","author":"Della Porta","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111903081715000_B33","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111903081715000_B34","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","article-title":"The genetic basis of myelodysplasia and its clinical relevance","volume":"122","author":"Cazzola","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111903081715000_B35","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.22240","article-title":"JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders","volume":"107","author":"Rumi","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111903081715000_B36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellann\u00e9-Chantelot","year":"2006","journal-title":"Blood"},{"issue":"35","key":"2019111903081715000_B37","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111903081715000_B38","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903081715000_B39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2015-09-668673","article-title":"Germline RBBP6 mutations in familial myeloproliferative neoplasms","volume":"127","author":"Harutyunyan","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"2019111903081715000_B41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"2019111903081715000_B42","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"2019111903081715000_B43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2016-07-726448","article-title":"JAK2 V617F clonal disorders: fate or chance?","volume":"128","author":"Vassiliou","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903081715000_B44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.beha.2014.07.002","article-title":"Hereditary erythrocytosis, thrombocytosis and neutrophilia","volume":"27","author":"Hong","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"2019111903081715000_B45","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111903081715000_B46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-12-473777","article-title":"A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis","volume":"123","author":"Etheridge","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111903081715000_B47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111903081715000_B48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903081715000_B49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111903081715000_B50","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia","volume":"98","author":"Barosi","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B51","first-page":"1123","article-title":"Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"issue":"24","key":"2019111903081715000_B52","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"issue":"9501","key":"2019111903081715000_B53","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"2019111903081715000_B54","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2019111903081715000_B55","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111903081715000_B56","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B58","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903081715000_B59","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood-2016-01-694182","article-title":"Mutant calreticulin: when a chaperone becomes intrusive","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111903081715000_B60","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2019111903081715000_B61","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111903081715000_B62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"7","key":"2019111903081715000_B63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111903081715000_B64","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2019111903081715000_B65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1413718","article-title":"A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm","volume":"372","author":"Cabagnols","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111903081715000_B66","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2014-12-616847","article-title":"CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation","volume":"125","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903081715000_B67","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-03-632893","article-title":"Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1","volume":"125","author":"Loghavi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903081715000_B68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2019111903081715000_B69","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111903081715000_B70","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111903081715000_B71","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"2019111903081715000_B72","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"2019111903081715000_B73","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111903081715000_B74","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"16","key":"2019111903081715000_B75","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903081715000_B76","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111903081715000_B77","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111903081715000_B78","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111903081715000_B79","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"2019111903081715000_B80","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111903081715000_B81","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2019111903081715000_B82","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111903081715000_B83","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903081715000_B84","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2019111903081715000_B85","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111903081715000_B86","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","article-title":"Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111903081715000_B87","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"2019111903081715000_B88","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"23","key":"2019111903081715000_B89","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111903081715000_B90","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"33","key":"2019111903081715000_B91","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903081715000_B92","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111903081715000_B93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111903081715000_B94","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"issue":"32","key":"2019111903081715000_B95","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111903081715000_B96","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019111903081715000_B97","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111903081715000_B98","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111903081715000_B99","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111903081715000_B100","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903081715000_B101","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111903081715000_B102","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/680\/1402104\/blood695957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/6\/680\/1402104\/blood695957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:08:40Z","timestamp":1574132920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/6\/680\/36332\/Diagnosis-risk-stratification-and-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-10-695957","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}